FDA approves NVS' Cosentyx in hidradenitis suppurativa for adolescents

Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the drug for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population. The approval makes Cosentyx the only IL-17A inhibitor currently available for this patient population and expands treatment options for adolescents living...